Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve was acquired by Eli Lilly in 2025.
Status: Public
Pony.ai
Founded in late 2016 by former Baidu Chief Architect James Peng (CEO) and programming legend Tiancheng Lou (CTO), Pony.ai aims to revolutionize the future of transportation by building the safest and most reliable self-driving technology.
An Eight Roads investment. Eight Roads is F-Prime’s sister venture capital investment group, with which F-Prime collaborates on investments outside of the Americas and Europe.
Sana Biotechnology
Sana Biotechnology, Inc. (NASDAQ: SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease.
Seyond
Seyond (formerly Innovusion) is a leading developer of image-grade LiDAR sensor systems for level 4+ of the autonomous vehicle market. Its unique combination of range, resolution, hardware accelerated sensor fusion, compact size, ease of integration and cost effectiveness makes its products an ideal choice for the most demanding applications.
Beam Therapeutics
Beam Therapeutics (NASDAQ: BEAM) is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Tempest Therapeutics
Tempest Therapeutics (Nasdaq: TPST) is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
Cytek Biosciences
Cytek Biosciences Inc. (NASDAQ: CTBK) is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capabilities.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade. Acquired by Biogen in 2026.
Checkmate Pharmaceuticals
Checkmate Pharmaceuticals (NASDAQ: CMPI) is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. Checkmate Pharmaceuticals was acquired by Regeneron (NASDAQ: REGH) in 2022.
Turnstone Biologics
Turnstone Biologics (NASDAQ: TSBX) is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.